Does Vaping Cause Weight Loss? Evidence Review (Mechanism, EVALI, Addiction)

The honest answer: mechanistically yes — vape-delivered nicotine activates the same POMC/MC4R appetite-suppression pathway as cigarettes — but clinically no. The mechanism is the Audrain-McGovern + Benowitz 2011 Clin Pharmacol Ther review^[1]. The 2019–2020 EVALI outbreak^[2][3] killed 68 and hospitalized roughly 2,800 mostly via vitamin E acetate in illicit THC vapes. The Wang 2019 MMWR National Youth Tobacco Survey^[4] documented current e-cigarette use among 27.5% of high-school students. Nicotine’s acute sympathomimetic cardiovascular profile^[5] (heart rate +10–15 bpm, blood pressure rise, coronary vasoconstriction) operates the same way through vape aerosol as through cigarettes. Magnitude vs GLP-1 receptor agonists is not close: STEP-1 semaglutide^[6] −14.9% TBWL; SURMOUNT-1 tirzepatide^[7] −20.9%. Vape’s nicotine-mediated ~5 lb effect is roughly 5-fold smaller and comes with an addiction profile, ongoing lung-injury concern, and (for adolescents) developing-brain neurotoxicity. No obesity-medicine guideline endorses vaping for weight loss. Below: device types, nicotine concentrations, the POMC mechanism, the EVALI story, addiction and cardiovascular profile, magnitude vs GLP-1s, and what actually works.

At a glance — Vaping and body weight

• The active ingredient for appetite suppression is nicotine, not the vape vehicle. Vape-delivered nicotine binds the same α3β4 and α4β2 nicotinic acetylcholine receptors in the hypothalamic arcuate nucleus and activates the same POMC neuron / α-MSH / MC4R pathway as cigarette-delivered nicotine (Audrain-McGovern + Benowitz 2011)^[1]. The mechanism is route-independent.
• Effect size is roughly cigarette-comparable: ~5 lb. The population-level appetite-suppression and thermogenesis attributable to chronic nicotine exposure is on the order of 4–5 kg, derived from smoking-cessation cohort data. Vape delivery does not change the pharmacology of nicotine itself, although peak plasma concentrations vary widely by device, pod chemistry (freebase vs salt), and user-puff behavior.
• Nicotine concentration in vape products spans 3–50+ mg/mL. Freebase nicotine refill liquids typically run 3–24 mg/mL. Closed-system pod devices (Juul, Vuse Alto, NJOY) commonly use nicotine salts at 35–59 mg/mL — a 5%-strength Juul pod delivers nicotine equivalent to roughly a pack of cigarettes per pod. Disposable vapes (Elf Bar, Lost Mary, Geek Bar) at the 5% nicotine-salt formulation can deliver multiple packs’ worth of nicotine exposure per device.
• EVALI was a real outbreak. In 2019–2020 the CDC documented an outbreak of e-cigarette or vaping product use–associated lung injury (EVALI) with 2,807 hospitalized cases and 68 deaths nationally. The Blount NEJM 2020 BAL analysis^[2] identified vitamin E acetate (a thickening agent used in illicit-market THC vape cartridges) as the primary culprit, with detection in 48 of 51 BAL samples (94%). The Layden NEJM final report^[3] on 98 Illinois/Wisconsin patients: median age 21, 79% male, 95% admitted, 26% required mechanical ventilation.
• Youth-vaping epidemic is the population-level concern. The Wang 2019 MMWR National Youth Tobacco Survey^[4] documented current e-cigarette use at 27.5% of U.S. high-school students and 10.5% of middle-school students in 2019 — a surveillance signal that prompted FDA flavor restrictions and the U.S. Surgeon General “epidemic” designation. Adolescent nicotine exposure harms developing reward and executive-function circuits.
• Acute cardiovascular cost is real. Nicotine delivered by any route, including vape aerosol, raises heart rate 10–15 bpm acutely, raises systolic and diastolic blood pressure, and produces coronary vasoconstriction (Benowitz 2010 NEJM^[5]). The sympathomimetic mechanism that drives the desired appetite effect also drives the unwanted cardiovascular effect.
• Magnitude is small vs GLP-1s. Vape’s ~5 lb nicotine effect is roughly 5-fold below STEP-1 semaglutide^[6] (−14.9% TBWL) and 7-fold below SURMOUNT-1 tirzepatide^[7] (−20.9%). Even phentermine monotherapy, naltrexone/bupropion, and orlistat produce comparable or larger magnitudes without the addiction and lung-injury profile.
• This is NOT a recommendation. No obesity-medicine guideline (AACE, The Obesity Society, Endocrine Society) recommends vaping for weight management. The CDC e-cigarette information page and the U.S. Surgeon General’s reports characterize youth and never-smoker vape use as net harm. The FDA reduced-risk framework applies to adult-smoker switching, not to never-smoker initiation.

Vape device types — what is in your pocket

The category “vape” covers several distinct device architectures with different nicotine-delivery characteristics:

• Closed-system pod devices (Juul, Vuse Alto, NJOY ACE). Disposable prefilled pods snap into a rechargeable battery. Nicotine-salt formulation at 3–5% strength (roughly 35–59 mg/mL). Pharmacokinetically the closest commercial vape to a cigarette — rapid plasma nicotine peak, smooth throat sensation (nicotine salts are less harsh than freebase), high reinforcement potential. A 5% Juul pod is roughly equivalent to a pack of cigarettes in delivered nicotine. The dominant U.S. closed-pod market for years was Juul; current market leaders (post-FDA flavor restriction enforcement) shift frequently.
• Refillable open-system devices (vape pens, box mods, tanks). User-refilled with freebase nicotine e-liquid at 0–24 mg/mL. Larger battery and atomizer, more configurable wattage, larger aerosol volume per puff. Plasma nicotine peak is dose-dependent on liquid concentration and inhalation pattern. The original “vape” category before pod devices.
• Disposable vapes (Elf Bar, Lost Mary, Geek Bar, Esco Bars, Breeze Pro, Fume). Single-use, non-refillable, prefilled with nicotine-salt e-liquid at 2–5%, with battery and atomizer integrated. Many high-puff-count products (5,000–10,000+ puffs per device) contain a multi-pack equivalent of nicotine in one disposable. Most of these products are NOT FDA-authorized for marketing in the U.S. but are widely sold via convenience stores and online. The current dominant vape category among adolescent and young adult users.
• Heat-not-burn tobacco devices (IQOS, Glo). Technically distinct from e-cigarettes — uses real tobacco heated below combustion temperature rather than nebulized e-liquid. FDA authorized IQOS as a modified-risk tobacco product but it was withdrawn from the U.S. market in 2021 over IP litigation. Reintroduction announced 2024–2025. Not discussed further in this article; nicotine pharmacokinetics are intermediate between cigarettes and vapes.
• Nicotine pouches (Zyn, On!, Velo). Not a vape — oral-mucosa nicotine pouches with no aerosol or combustion. Discussed separately in our does nicotine help with weight loss evidence review companion article.
• THC and CBD vapes. A separate product category using cannabis extracts, often with diluents (medium-chain triglycerides, vitamin E acetate historically, polyethylene glycol, propylene glycol, glycerin). Most of the EVALI outbreak was traced to illicit-market THC vapes containing vitamin E acetate as a thickening agent. Discussed separately in our does smoking weed cause weight loss evidence review.

The mechanism: vape nicotine = cigarette nicotine

For appetite and body-weight effects, the pharmacology of vape nicotine is essentially the pharmacology of any inhaled nicotine. The Audrain-McGovern + Benowitz 2011 review^[1] describes the pathway, and the route-of-delivery substitution does not change the downstream CNS targets:

• Pulmonary absorption is fast. Vape aerosol deposits in the alveolar and bronchial epithelium, where nicotine is absorbed into the pulmonary venous circulation and reaches the brain within 10–30 seconds — comparable to combustible cigarettes. Nicotine-salt formulations have slightly different absorption profiles vs freebase but still deliver to brain within seconds.
• Nicotinic acetylcholine receptor binding. Nicotine crosses the blood-brain barrier and binds α3β4 and α4β2 nAChRs in the CNS. nAChRs are pentameric ligand-gated ion channels producing fast neuronal depolarization.
• POMC neuron activation in the arcuate nucleus. Nicotine selectively activates POMC (pro-opiomelanocortin) neurons via α3β4 nAChRs; activated POMC neurons release α-MSH.
• MC4R downstream signaling. α-MSH binds melanocortin-4 receptors on second-order neurons in the paraventricular nucleus. MC4R activation suppresses food intake and increases energy expenditure — the same pathway that melanocortin-pathway obesity drugs target directly and that GLP-1 receptor agonists ultimately recruit.
• Sympathetic thermogenesis. Nicotine stimulates peripheral catecholamine release (epinephrine, norepinephrine) from the adrenal medulla and sympathetic nerve terminals, driving β-adrenergic thermogenesis in skeletal muscle and brown adipose tissue — a small but measurable bump in resting energy expenditure.
• Net effect: ~4–5 kg lower body weight. The population-level body-weight effect attributable to chronic nicotine exposure is on the order of 4–5 kg, derived from smoking-cessation cohort data and applied to vape users by mechanistic equivalence. Vape-specific weight-effect RCTs are limited; the closest data come from smoking-cessation trials in which subjects switched to vapes vs continued smoking vs quitting outright.

Nicotine concentration variability: 3–50+ mg/mL

One under-appreciated feature of the vape market is the enormous range of nicotine concentrations available. This matters for both the magnitude of any weight effect and the magnitude of cardiovascular and addiction risk.

• Freebase nicotine e-liquids: 0, 3, 6, 12, 18, 24 mg/mL. Refillable open-system devices traditionally use freebase nicotine across this dose ladder. 0 mg/mL is nicotine-free (vapor only); 18–24 mg/mL approximates pack-a-day-smoker dosing in heavy users.
• Nicotine-salt e-liquids: 20, 35, 50, 59 mg/mL. Pod-system devices (Juul, Vuse, NJOY) and most disposables use nicotine salts (typically nicotine benzoate or nicotine lactate) which buffer the nicotine to a less alkaline pH, reducing throat-hit harshness and permitting higher concentrations to be inhaled comfortably. 5% strength corresponds to roughly 50–59 mg/mL depending on density. A single 5% Juul pod (0.7 mL) contains approximately 40 mg of nicotine — equivalent to roughly 20 cigarettes’ worth.
• Disposable high-puff-count devices. Many of the dominant disposable vape brands (Elf Bar BC5000, Lost Mary OS5000, Geek Bar Pulse) advertise 5,000 puffs per device at 5% nicotine in 13–15 mL tank size. That is approximately 650–750 mg of total nicotine per disposable — multiple packs of cigarettes’ worth in one ~$15 device. Users who finish a disposable in 3–5 days are dosing in the heavy-smoker range.
• EU regulation caps at 20 mg/mL. The European Union Tobacco Products Directive limits e-liquid nicotine strength to 20 mg/mL maximum. The U.S. has no analogous federal cap; FDA enforcement is largely focused on PMTA (premarket tobacco application) compliance and youth-flavor marketing. U.S. disposables exceed EU caps by 2.5–3-fold.
• Implication for weight effect. A 0 mg/mL (nicotine-free) vape will not suppress appetite. Higher nicotine concentrations approximately scale the weight effect and the addiction/cardiovascular risk in parallel.

EVALI 2019–2020: vitamin E acetate and 68 deaths

The 2019–2020 e-cigarette or vaping product use–associated lung injury (EVALI) outbreak is the single most consequential clinical event in the vape category to date. It deserves its own section because it shaped public-health understanding of vape safety.

• Outbreak scale. Per CDC final tally, 2,807 hospitalized cases and 68 deaths across all 50 states, the District of Columbia, and 2 U.S. territories between mid-2019 and early 2020. Median patient age 24; 66% male. About 76% reported THC-containing vape product use; 32% reported nicotine-only product use; the remainder reported both.
• Clinical syndrome. The Layden NEJM 2020 final report^[3] characterized 98 Illinois/Wisconsin patients: 95% admitted to hospital, 26% required mechanical ventilation, presentations included respiratory symptoms (97%), GI symptoms (77%), and constitutional symptoms (100%). Imaging showed bilateral pulmonary infiltrates, often with a ground-glass pattern.
• Vitamin E acetate identified as primary culprit. The Blount NEJM 2020 BAL analysis^[2] tested bronchoalveolar-lavage fluid from 51 EVALI patients across 16 states. Vitamin E acetate was detected in 48 of 51 (94%) patient samples. THC was detected in 40 of 47 tested (85%). Vitamin E acetate was being used as a thickening or cutting agent in illicit-market THC vape cartridges. Bench experiments showed vitamin E acetate aerosolized under heated conditions produces ketene, a potent pulmonary irritant.
• Outbreak attenuation. After CDC, state, and law-enforcement actions removed vitamin E acetate from the illicit-market supply chain — combined with public messaging warning against unregulated THC vapes — new case counts dropped sharply in early 2020. The COVID-19 pandemic complicated final-tally surveillance.
• The clinical signal beyond vitamin E acetate. Even nicotine-only vapes produced EVALI in a minority of cases. The lung is not engineered to receive aerosolized propylene glycol, vegetable glycerin, flavoring chemicals (diacetyl, 2,3-pentanedione — both linked to bronchiolitis obliterans in occupational exposure), heavy metals from atomizer coils, or ultrafine particulate. Long-term pulmonary effects of chronic vape exposure remain incompletely characterized.
• EVALI is not over. While outbreak-scale case counts dropped, sporadic EVALI presentations continue, and surveillance for newly introduced vape additives is ongoing. The general framing is: aerosolized lung delivery of complex chemical mixtures is a new exposure with incompletely understood long-term consequences.

Addiction: faster than cigarettes for adolescents

Vape devices — especially nicotine-salt pod and disposable formulations — combine rapid pulmonary delivery, palatable flavors, discreet form factor, and very high per-device nicotine content. The Benowitz 2010 NEJM nicotine-addiction review^[5] describes the pharmacology of nicotine dependence; vape delivery achieves it at least as efficiently as cigarettes:

• Rapid CNS delivery. Inhaled vape nicotine reaches the brain in 10–30 seconds — the same rapid-onset reinforcement that drives cigarette dependence. Nicotine salts permit higher per-puff nicotine delivery without throat irritation, allowing users to ingest more nicotine per session.
• Pod and disposable form factors normalize chronic use. Unlike cigarettes (10–15 minute discrete smoking session producing 1–2 mg nicotine), vape pods and disposables enable continuous “stealth” use throughout the day — in classrooms, offices, bathrooms, cars, bedrooms. Total daily nicotine intake among heavy vape users frequently exceeds heavy smokers’ intake.
• Withdrawal is real. DSM-5 nicotine withdrawal symptoms (irritability, anxiety, difficulty concentrating, restlessness, increased appetite, depressed mood, insomnia) apply regardless of nicotine-delivery route. Among regular vape users attempting cessation, withdrawal intensity and relapse rates are comparable to or higher than cigarette quitters.
• Adolescent dependence develops fast. The DANDY-era literature established that meaningful dependence symptoms emerge within weeks of regular nicotine use in adolescents. The Wang 2019 MMWR National Youth Tobacco Survey^[4] documented 27.5% of high-school students and 10.5% of middle-school students currently using e-cigarettes — the largest adolescent nicotine-use population in modern U.S. surveillance history. The U.S. Surgeon General has repeatedly emphasized that adolescent nicotine exposure harms developing reward and executive-function circuits and increases lifetime dependence risk.
• Vape-to-cigarette transition risk. Longitudinal studies of adolescent vape initiators show elevated odds of later transition to combustible cigarettes vs never-vape adolescent controls — the inverse of the adult-smoker-switching framework.
• Cessation programs exist. The CDC, NIH, and Truth Initiative operate vape-cessation resources (truth’s This Is Quitting text-message program, the National Cancer Institute SmokefreeTXT, 1-800-QUIT-NOW). Varenicline and NRT, while FDA-approved for combustible-cigarette cessation, are commonly used off-label or in clinical-trial contexts for vape cessation with mixed evidence.

Cardiovascular risk: same sympathomimetic mechanism

Vape nicotine is not pharmacologically distinct from cigarette-delivered nicotine with respect to acute cardiovascular effects. The Benowitz 2010 NEJM review^[5] documents the sympathomimetic pharmacology that operates regardless of delivery route:

• Acute heart-rate rise. Inhaled nicotine raises heart rate by approximately 10–15 bpm acutely. The magnitude scales with delivered dose and is reproduced in vape studies measuring sympathetic activation.
• Blood-pressure rise. Systolic and diastolic blood pressure rise acutely with each nicotine bolus. High-frequency pod or disposable use throughout the day maintains elevated sympathetic tone.
• Coronary vasoconstriction. α-adrenergic stimulation produces coronary vasoconstriction acutely. In patients with established coronary disease this is the mechanism by which any nicotine exposure (combusted, vaped, oral, or transdermal) can precipitate angina or ischemic events.
• Platelet activation and endothelial dysfunction. Nicotine activates platelets and impairs endothelial-dependent vasodilation acutely. Chronic exposure contributes to atherogenic processes.
• Vape-specific cardiovascular literature is developing. Vapes have been studied since the mid-2010s for cardiovascular endpoints, with studies showing acute sympathetic activation comparable to cigarettes, oxidative stress markers in serum, and impaired flow-mediated dilation. Long-term cardiovascular outcomes (MI, stroke, cardiovascular death) require longer follow-up than is currently available but the acute-effect literature is consistent.
• Pregnancy contraindication. Nicotine in any form is contraindicated in pregnancy. Effects on fetal development include low birthweight, preterm birth, and neurodevelopmental effects. Vape aerosol additionally exposes the fetus to propylene glycol, glycerin, and flavoring chemicals of incompletely characterized fetal-effect profile.

Vape switching vs vape cessation

Two clinical contexts deserve separate framing, because the risk-benefit calculus differs sharply:

• Adult smoker switching from cigarettes to vape (harm-reduction framework). The FDA modified-risk tobacco product (MRTP) pathway has authorized certain tobacco-flavored e-cigarette products as switching aids for adult smokers unable or unwilling to quit nicotine entirely. The premise: vape combustion-product exposure is lower than cigarette combustion-product exposure, so net harm to a continuing smoker is reduced. This is not a weight-loss framework — the smoker is already nicotine-dependent and continues to receive the same appetite-suppression effect via the new route.
• Never-smoker initiating vape (initiation framework). For a never-smoker, vape initiation introduces a new chronic-nicotine exposure with addiction, cardiovascular, and incompletely characterized pulmonary risks. The weight-effect benefit (~5 lb attributable to nicotine) is decisively outweighed by these risks. No public-health agency recommends initiation of vaping in a never-smoker for any reason, weight loss included.
• Vape user attempting cessation (cessation framework). Quitting vapes produces nicotine-withdrawal symptoms including increased appetite, mirror-image to the appetite-suppression effect during chronic use. Post-cessation weight gain is expected. Cessation pharmacotherapy options include NRT (off-label for vape cessation, on-label for cigarette cessation), varenicline (off-label for vape cessation), bupropion, and behavioral programs (truth’s This Is Quitting, SmokefreeTXT, 1-800-QUIT-NOW). Long-term outcomes of cessation outweigh the 4–5 kg average weight gain.
• NRT vs vape switch for cigarette quitters. Some clinicians prefer FDA-approved NRT (patch, gum, lozenge) over vape switching because NRT has a clear endpoint (tapering schedule, lower per-day nicotine dose) and lacks the pulmonary aerosol exposure. Others view vape switching as better suited to smokers who have failed NRT or who report the behavioral and sensory components of smoking as the dependence driver, not just nicotine. The evidence base modestly favors combination NRT or varenicline over vape switching for sustained 1-year abstinence, but real-world outcomes vary.

Magnitude: vape nicotine vs GLP-1 RAs

Cross-comparison caveat: vape-specific RCTs for body weight are limited; the magnitude estimate derives from cigarette-cessation cohort data applied to vape by mechanistic equivalence. GLP-1 figures are RCT primary endpoints in randomized-to-treatment populations. Even taking vape’s ~5 lb nicotine-attributable signal at face value, it is roughly 5–7-fold smaller than GLP-1 RCT endpoints and is achieved through chronic exposure to an addictive sympathomimetic with documented acute cardiovascular cost.

Why this is NOT a weight-loss strategy

Putting it all together: vape-delivered nicotine has the same mechanistically coherent appetite-suppressing and modestly thermogenic effect as cigarette-delivered nicotine, producing roughly 4–5 kg of population-level body-weight difference. But translating this into a weight-loss recommendation fails on multiple fronts:

• Effect size is small vs evidence-based pharmacotherapy. ~5 lb is roughly 5-fold below STEP-1 semaglutide^[6] and 7-fold below SURMOUNT-1 tirzepatide^[7]. Even older monotherapies like orlistat or phentermine deliver comparable or larger magnitudes without the addiction profile or pulmonary exposure.
• Acquisition cost is severe. The only way to maintain the nicotine effect on body weight is chronic daily vape use. Daily disposable use at common consumption rates runs roughly $60–$120/month. Closed-pod systems run $40–$80/month. Open-system refillable devices have lower per-month consumable costs but higher upfront equipment investment. Compared with the per-month cost of a generic GLP-1 or older obesity drug, vape is not meaningfully cheaper.
• Cardiovascular trade is bad. The sympathomimetic mechanism that drives the thermogenic-and-appetite-suppression effect also drives tachycardia, hypertension, and coronary vasoconstriction. You cannot pharmacologically dissociate the desirable from the undesirable.
• Addiction profile is severe. Vape nicotine dependence develops fast, especially with nicotine-salt formulations. Initiating vape deliberately for weight loss creates a high-probability long-term dependency.
• Lung-injury risk is not zero. EVALI taught the field that aerosolized lung delivery of complex chemical mixtures is a new exposure with incompletely characterized long-term consequences. Vitamin E acetate has been removed from the regulated supply chain but illicit-market formulations continue to evolve, and the long-term effects of chronic exposure to propylene glycol, glycerin, flavoring chemicals, and trace metals are not fully known.
• For adolescents, neurotoxicity is a separate issue. Adolescent nicotine exposure harms developing brain reward and executive-function circuits. The Wang 2019 MMWR National Youth Tobacco Survey^[4] documented a 27.5% high-school current-use rate. Initiating vape deliberately for weight loss in an adolescent is the same decision as initiating cigarettes for weight loss in an adolescent — both are harmful.
• No guideline supports it. No obesity-medicine society, no smoking-cessation guideline, no FDA-approved indication endorses vape use for weight loss. The clinical consensus is unambiguous.

If you don’t already vape, don’t start to lose weight

This deserves its own section because the question “should I start vaping to lose weight?” is the wrong question on its face. Several distinct cases:

• Never-smoker, never-vape adult asking if vape will help lose weight. Answer: no. Initiating any nicotine delivery system in a never-user trades a high-probability long-term addiction profile and acute cardiovascular cost for a modest (~5 lb) weight effect that is 5-fold smaller than a GLP-1 receptor agonist would deliver. The risk-benefit is decisively unfavorable.
• Never-smoker, never-vape adolescent asking if vape will help lose weight. Answer: no, and the adolescent framing adds developing-brain neurotoxicity and elevated lifetime-dependence risk on top of the adult considerations. The U.S. Surgeon General has repeatedly characterized adolescent vape use as a public-health epidemic.
• Current smoker switching to vape because of cigarettes plus interested in weight effect. Switching from cigarettes to vape does not produce additional weight loss beyond the cigarette baseline — the active ingredient (nicotine) is the same and the dose may be similar. Switching may produce harm reduction on combustion-product exposure (tar, CO, polycyclic aromatic hydrocarbons) but is not a weight-loss intervention. Talk to your clinician about cessation; varenicline has the highest 1-year quit-rate evidence.
• Current vape user wondering if it’s helping with weight. Probably modestly, via the nicotine mechanism. The dependence and cardiovascular costs are ongoing. Cessation is the recommended direction, even with the expected 4–5 kg post-cessation weight gain.
• Current vape user attempting cessation and worried about weight gain. Common, expected, and treatable. A GLP-1 receptor agonist is a reasonable consideration if you meet BMI criteria. The cardiovascular and pulmonary benefit of having quit vape far exceeds the weight-gain cost. Quit support: truth’s This Is Quitting (text DITCHVAPE to 88709), SmokefreeTXT, 1-800-QUIT-NOW.

What to use instead

For a person interested in pharmacologic weight loss, the evidence-based options are well-defined:

• GLP-1 receptor agonists. Wegovy (semaglutide 2.4 mg) delivered −14.9% TBWL in STEP-1^[6]. Zepbound (tirzepatide 15 mg) delivered −20.9% in SURMOUNT-1^[7]. Both are FDA-approved for chronic weight management in adults with BMI ≥ 30, or ≥ 27 with a weight-related comorbidity. Oral semaglutide for obesity is in late-stage development.
• Combination drugs. Contrave (bupropion + naltrexone) delivers roughly 5–9% TBWL in RCTs. Phentermine/topiramate (Qsymia) delivers 8–10% TBWL. Both are FDA-approved.
• Older monotherapies. Phentermine (sympathomimetic, short-term use), orlistat (lipase inhibitor, modest magnitude, GI side effects).
• Bariatric procedures where appropriate. Sleeve gastrectomy, Roux-en-Y gastric bypass, endoscopic options (intragastric balloon, ESG).
• Intensive lifestyle intervention. Structured diet (calorie deficit, adequate protein, controlled added sugars), resistance plus aerobic exercise, sleep hygiene, and behavioral therapy. Magnitude is modest (3–8% TBWL in well-conducted trials) but the foundation underlying every other intervention.
• Drug-effect lookup. Many non-GLP-1 medications affect weight in either direction. The non-GLP-1 drug weight-effect lookup tool on WLR catalogs drugs that cause loss and gain.

When to talk to a clinician

Vape use touches several different clinician conversations:

• If you currently vape and want to quit. Your primary care clinician can recommend behavioral support (truth’s This Is Quitting text-message program, SmokefreeTXT, 1-800-QUIT-NOW) and may use NRT, varenicline, or bupropion off-label for vape cessation. The expected 4–5 kg post-cessation weight gain is real but dwarfed by the cardiovascular, pulmonary, and addiction-resolution benefits. The CDC’s e-cigarette information page summarizes the public-health framing.
• If you vape and have noticed appetite suppression. The mechanism is real but the long-term costs (addiction, cardiovascular, lung-injury) outweigh the benefit. Talk to your clinician about cessation.
• If you smoke and are considering vape as a switching aid. Varenicline (Chantix) has the highest 1-year quit-rate evidence; combination NRT (patch plus gum or lozenge) is the next-best. Vape switching can serve as a harm-reduction step for smokers who have failed cessation pharmacotherapy but is not first-line in most clinical frameworks.
• If you are on a GLP-1 RA and also vape or smoke. No FDA-label drug-drug interaction exists between GLP-1s and nicotine. The combination is not contraindicated but the cardiovascular and pulmonary risks of continued nicotine exposure remain — cessation is the priority. Many GLP-1 patients find that the appetite-suppression on the GLP-1 makes a vape or smoking cessation attempt feel easier.
• If you have respiratory symptoms and use any vape product. See your clinician promptly. While the 2019–2020 EVALI outbreak attenuated after vitamin E acetate removal, sporadic EVALI continues to be reported and the differential diagnosis for cough, dyspnea, chest pain, or constitutional symptoms in vape users includes EVALI, pneumonia, pulmonary embolism, and cardiac causes.
• If you are considering starting vape for weight loss. Don’t. The risk-benefit is decisively unfavorable. The same clinician conversation that addresses weight management has better tools available.

Bottom line

• Mechanistically yes: vape-delivered nicotine activates the same POMC/MC4R appetite-suppression pathway (Audrain-McGovern + Benowitz 2011^[1]) and produces the same modest sympathetic thermogenesis as cigarette nicotine. Route of delivery does not change the downstream pharmacology.
• Quantitatively: the population-level body-weight effect attributable to chronic nicotine exposure is on the order of ~5 lb / 4–5 kg — comparable between cigarettes and vapes when delivered nicotine doses are similar.
• Clinically no: EVALI 2019–2020 (2,807 hospitalizations, 68 deaths) anchored the lung-injury concern^[2][3]. Acute cardiovascular effects (heart rate +10–15 bpm, blood-pressure rise, coronary vasoconstriction) operate the same way through vape aerosol as through cigarettes^[5]. Adolescent dependence epidemic (27.5% high-school current use^[4]) anchors the youth concern. No obesity-medicine guideline endorses vape use for weight management.
• Magnitude is small vs GLP-1s. STEP-1 semaglutide^[6] delivered −14.9% TBWL; SURMOUNT-1 tirzepatide^[7] −20.9%. Vape’s ~5 lb nicotine signal is roughly 5–7-fold smaller.
• Don’t start vaping if you don’t already. Never-smoker, never-vape adults and adolescents who initiate vape for weight loss trade a high-probability long-term addiction and cardiovascular cost for a modest weight effect that is 5-fold smaller than a GLP-1 receptor agonist would deliver.
• Vape switching is for adult smokers, not for weight. The FDA modified-risk pathway authorizes certain tobacco-flavored e-cigarettes as switching aids for adult smokers unable to quit nicotine entirely — not as a weight-loss intervention and not for never-smokers.
• Cessation is the direction. If you currently vape, the priority is cessation. Behavioral support (truth’s This Is Quitting, SmokefreeTXT, 1-800-QUIT-NOW) plus off-label NRT, varenicline, or bupropion as your clinician recommends. Post-cessation weight gain is normal and treatable.

Related research

• Does nicotine help with weight loss? Evidence review (mechanism, risks)
• Does smoking weed cause weight loss? Honest evidence review
• Does anxiety cause weight loss? Evidence review (mechanism, GI symptoms, sleep)
• GLP-1 side-effect questions answered
• Non-GLP-1 drug weight-effect lookup tool

Important disclaimer. This article is educational and does not constitute medical advice. Vaping (electronic cigarettes, e-cigarettes, vape pods, disposable vapes) is not FDA-approved for weight loss, obesity, or any weight-management indication. The FDA modified-risk tobacco product (MRTP) pathway applies to adult smokers seeking to switch from combustible cigarettes, not to never-smoker initiation. Any vape product introduces an addiction profile, an acute sympathomimetic cardiovascular cost, and an incompletely characterized long-term pulmonary-exposure profile. The 2019–2020 EVALI outbreak documented serious acute lung injury linked primarily to vitamin E acetate in illicit-market THC vapes. Adolescent vape use carries developing-brain neurotoxicity and elevated lifetime-dependence risk on top of the adult considerations. Decisions about vape initiation, switching, or cessation — particularly alongside prescription medications like GLP-1 receptor agonists — belong with a qualified clinician who knows your full medical history. If you currently vape and want to quit: text DITCHVAPE to 88709 (truth’s This Is Quitting), text QUIT to 47848 (SmokefreeTXT), or call 1-800-QUIT-NOW.